Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > Keep patient, maybe we are at last step to the final victory
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(182)
•••
Comment by Alamir1111on May 16, 2024 4:29pm
132 Views
Post# 36044244

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Keep patient, maybe we are at last step to the final victory

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Keep patient, maybe we are at last step to the final victoryhttps://stockhouse.com/news/press-releases/2024/05/02/theralase-r-expands-clinical-team



So my hunch is that the following happened
1. Preliminary Breakthrough Therapy Designation Advice Request was held and the advisor didn't say NO or YES but rather, maybe but you need more information (central lab and further out data) to compensate for lack of biopsies and to just be more confident.

During the conference with the FDA, Theralase may have been advised that a definitively better durable response at 24 months would clearly demonstrate an improvement over available treatments which is a requirement for BTD and (hopefully) AA.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities